PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company focused on discovering and developing antibody therapeutics for the treatment of neurodegenerative diseases, including Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). Headquartered in Toronto, Canada, the company utilizes its proprietary target discovery platform to identify toxic misfolded protein structures that drive disease progression. ProMIS's lead product candidate, PMN310, is a humanized monoclonal antibody designed to selectively target toxic oligomers of amyloid beta in Alzheimer's disease and is currently in clinical development. The company's pipeline also includes PMN267 for ALS and PMN442 for MSA, both targeting toxic oligomeric forms of alpha-synuclein and TDP-43 proteins respectively. ProMIS differentiates itself through its precision medicine approach, which aims to target the most toxic species of misfolded proteins while avoiding non-toxic forms, potentially reducing side effects associated with broader targeting approaches. The company advances its programs through strategic partnerships and maintains collaborations with academic institutions to support its research efforts. ProMIS operates as a publicly traded entity on the OTCQB market under the ticker symbol ARFXF and on the Toronto Stock Exchange as PMN, funding its operations primarily through equity financings and strategic agreements.